New service at Eurosafe : Evaluation of the cutaneous microbiome !

New service at Eurosafe : Evaluation of the cutaneous microbiome !

What is the cutaneous microbiome? The cutaneous microbiome is the genetic material of all the microbes that live on and inside the human skin environment.

What is the difference with the microbiota? The cutaneous microbiota is all the microorganisms that live in our skin.

What are the variations of the cutaneous microbiome? The cutaneous microbiome changes according to the anatomical areas of the skin, temperature, humidity, and the lipid contents. There are 3 main types of skin microenvironment: oily areas, wet areas and dry areas. The cutaneous microbiota of a person is rather stable in time, but changes a lot from one person to another (interindividual variability).

Why are we interested in the skin microbiome? Microorganisms are essential to the quality of the skin. An imbalance in the composition of the microbiota can cause skin disorders. Various factors, including the use of cosmetics can affect the skin microbiome. It is important today to be able to evaluate the efficacy of these products on the respect of the microbiome.

Which assay did you develop in collaboration with Eurosafe? In collaboration with Eurosafe, we have developed an experimental test protocol on volunteers, treated or not treated with the product. We will determine, by 16S metagenomic sequencing, the bacterial composition of cutaneous samples collected by Eurosafe during use tests. The statistical comparison between the treated zone and the untreated zone will make it possible to conclude that there is no major modification of the microbiota by the test product. Contrary to targeted approaches (culture for example), the metagenomic approach allows us to determine the exhaustive bacterial composition of the samples.

How do the Vaiomer and Eurosafe expertise complement each other in responding to this new service? Vaiomer, CRO based in Toulouse, has developed a unique expertise in the metagenomic study of samples with low bacterial content. Vaiomer offers its solid experience in targeted metagenomic analysis of 16S. Eurosafe, CRO based in Brittany, specialist in safety and efficacy testing of cosmetic products evaluates the cutaneous tolerance through a use test under dermatological control and take cutaneaous samples from the volunteers. Those samples are given to Vaiomer for the metagenomics analysis. The combined know-how of Eurosafe and Vaiomer allow cosmetics companies to evaluate the effectiveness of their products on claims related to the respect of the cutaneous microbiome.

News

    New service at Eurosafe : Evaluation of the cutaneous microbiome !

    We developed a new offer in collaboration with Vaiomer. For the launching, we interviewed them to tell you more about it. Find the interview below!

    Read More

    We are launching Wepredic !

    We are launching Wepredic! – A group that gathers key players in in vitro technologies Christophe Chesné, Ph.D, CEO of Biopredic International, is also the founder of Eurosafe, Starlight and Advancells. With their long-standing expertise in in vitro technologies for toxicology and pharmacokinetics, these companies daily help and support world’s leading pharmaceutical, cosmetic and chemical companies. Wepredic has been funded to unite these four brands and deliver in vitro testing solutions that aim to replace laboratory animals. Discover Christophe Chesné’s editorial on the reasons for this strategic move !

    Read More

    New logo and new brand identity for Eurosafe !

    As part of re-shaping the brands of the group Wepredic, our parent company, Eurosafe has been given a facelift. Our new logo captures the essence of our business activity: the safety evaluation of cosmetic and of pharmaceutical products!

    Read More

Last posters

  • Safety assessment of cosmetic ingredients for skin sensitization using QSAR in silico tool

    3/15/19

    Skin sensitization methods are developed to protect workers and consumers from chemical exposures. In 2012, OECD Test Guideline 168 (TG) addressed the 5 Key Events (KE) of the skin sensitization Adverse Outcome Pathway (AOP)[1]. To respond to cellular and tissue events(KE2, KE3) in vitro alternative methods were well described such as OECD TG 442C (Direct Peptide Reactivity Assay, DPRA); OECD TG 442D (KeratinoSens™) and OECD TG 442E (human Cell Line Activation Test, h-CLAT). The two biomarkers based test SENS-IS and the Genomic Allergic Detection Test (GARD) are under consideration by the OECD for the development of the respective TGs.

    Details
  • In silico prediction of Structure and compound affinity of Multidrug Resistance-associated Protein 2 (MRP2) for predicting hepatotoxicity.

    3/15/19

    MRP2 is an unidirectional efflux transporter mainly present in liver, that primarily transports organic anions, including drug conjugates and conjugated bilirubin. MRP2 supports a function in the terminal excretion and detoxification of endogenous and xenobiotic organic anions. Due to the lack of a X-ray structure of MRP2, there is no detail information about interaction of compounds with MRP2.

    Details
  • Cosmetics exposure data - Particular case of children from birth

    3/15/19

    It is commonly accepted that the Skin Surface Area over Body weight ratio (SA/BW) of infants and children is higher as compared with that in adults. Regarding the safety assessment process of cosmetic ingredients, Toxicological Reference Values (TRV) are expressed as mg/kg bw and the change in the ratio of surface area/body weight compared with an adult would give, according to A.G. Renwick (1998), a discrepancy of 2.3-fold for children at birth (except premature infants). Such inter individual variation is already covered by the generally accepted default value of 100 calculated for individual ingredients which is composed of 10 for interspecies variations (4.0 for toxicokinetics) and 10 for human variability, covering toxicokinetic (3.2) and toxicodynamic (3.2) differences between children and adults (A.G. Renwick (1998) and SCCS (2018)). Scheuplein et al. (2002) estimate that an uncertainty factor of 10 applied to this intra-species variability is a sufficiently powerful parameter to take into account child/adult variability, for children over 6 months old. This estimate may not be relevant for children under 6 months of age, in the absence of developmental or systemic toxicity studies. Given the ambiguity of these data, the question was raised whether the use of an increased uncertainty/safety factor would be relevant to cover children at birth exposure to cosmetic ingredients and ensure their safety under normal and reasonably foreseeable conditions of use.

    Details
  • In-silico modelization of compounds interaction with Bile salt Export Pump (BSEP): an alternative approach to predict hepatotoxicity

    3/15/19

    BSEP is an efflux transporter protein present in the hepatocytes membrane that plays important role in bile acid flow from hepatocyte cell into the bile canaliculi (1,2). Impaired BSEP activity due to drug interaction leads to accumulation of bile acid within the hepatocyte cells and results in cholestasis liver injury (DILI)(3). However, due to the lack of a X-ray structure of BSEP, there is no detail information about interaction of compounds with BSEP.

    Details
  • Use of SilensomesTM for the analysis of the inhibitory effect of Amiodarone on Warfarin metabolism

    3/1/19

    SilensomesTM correspond to batches of cryopreserved pooled of human liver microsomes (HLM) chemically silenced for one specific CYP450 using a mechanism based inhibitor (MBI) (1). SilensomesTM can be handled like conventional HLM. SilensomesTM allow qualitative CYP phenotyping, quantitative metabolized fraction (fm ) and intrinsic Clearance (Clint ) evaluation. It is well known that alterations of CYP mediated drug metabolism by simultaneous administration of other drugs is one of the most common causes of drug-drug interactions. One of them regards the possible effects of the antiarhythmic drug Amiodarone (AMIO) on the metabolism of warfarin (WRF). WRF is a widely used anticoagulant with a narrow therapeutic index and compounds affecting its metabolism may have serious consequences. WRF is mostly metabolized by CYP2C9, with the formation of different hydroxylated metabolites (OH-WRF) and AMIO is described to inhibit CYP2C9 (2). The studies reported here aimed to an in vitro experimental demonstration of the above prediction, to support the interpretation of the clinical data in a more robust manner. For that, we exploited Control SilensomesTM and CYP2C9 SilensomesTM, studying the involvement of CYP2C9 in the metabolism of S-WRF, and the effects of amiodarone on its metabolism.

    Details